Metsera Inc. Announces Positive Phase 1 Trial Results for Once-Monthly Amylin Candidate MET-233i, Showing Promising Weight Loss and No Safety Concerns

Reuters

09 Jun

<a href="https://laohu8.com/S/MTSR">Metsera Inc.</a> Announces Positive Phase 1 Trial Results for Once-Monthly Amylin Candidate MET-233i, Showing Promising Weight Loss and No Safety Concerns

Metsera Inc. (Nasdaq: MTSR) has announced positive topline results from its Phase 1 clinical trial of MET-233i, a once-monthly amylin analog. The trial demonstrated up to 8.4% mean placebo-subtracted weight loss at Day 36 and a 19-day half-life supporting monthly dosing. The results indicated that MET-233i was well-tolerated with no safety signals. The company plans to continue evaluating MET-233i both as a monotherapy and in combination with MET-097i. Topline data from the ongoing trials are anticipated by late 2025 or early 2026. Metsera will host a conference call and webcast on June 9, 2025, at 8:00 A.M. Eastern Time to discuss these findings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metsera Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9465181-en) on June 09, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2542386283"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2542386283\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2542386283?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-09 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2542386283","market":"us","top_or_hot":-1,"title":"Metsera Inc. Announces Positive Phase 1 Trial Results for Once-Monthly Amylin Candidate MET-233i, Showing Promising Weight Loss and No Safety Concerns","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MTSR\">Metsera Inc.</a> Announces Positive Phase 1 Trial Results for Once-Monthly Amylin Candidate MET-233i, Showing Promising Weight Loss and No Safety Concerns\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Metsera Inc. (Nasdaq: MTSR) has announced positive topline results from its Phase 1 clinical trial of MET-233i, a once-monthly amylin analog. The trial demonstrated up to 8.4% mean placebo-subtracted weight loss at Day 36 and a 19-day half-life supporting monthly dosing. The results indicated that MET-233i was well-tolerated with no safety signals. The company plans to continue evaluating MET-233i both as a monotherapy and in combination with MET-097i. Topline data from the ongoing trials are anticipated by late 2025 or early 2026. Metsera will host a conference call and webcast on June 9, 2025, at 8:00 A.M. Eastern Time to discuss these findings.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metsera Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9465181-en) on June 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Metsera Inc. Announces Positive Phase 1 Trial Results for Once-Monthly Amylin Candidate MET-233i, Showing Promising Weight Loss and No Safety Concerns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMetsera Inc. Announces Positive Phase 1 Trial Results for Once-Monthly Amylin Candidate MET-233i, Showing Promising Weight Loss and No Safety Concerns\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-09 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MTSR\">Metsera Inc.</a> Announces Positive Phase 1 Trial Results for Once-Monthly Amylin Candidate MET-233i, Showing Promising Weight Loss and No Safety Concerns\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Metsera Inc. (Nasdaq: MTSR) has announced positive topline results from its Phase 1 clinical trial of MET-233i, a once-monthly amylin analog. The trial demonstrated up to 8.4% mean placebo-subtracted weight loss at Day 36 and a 19-day half-life supporting monthly dosing. The results indicated that MET-233i was well-tolerated with no safety signals. The company plans to continue evaluating MET-233i both as a monotherapy and in combination with MET-097i. Topline data from the ongoing trials are anticipated by late 2025 or early 2026. Metsera will host a conference call and webcast on June 9, 2025, at 8:00 A.M. Eastern Time to discuss these findings.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metsera Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9465181-en) on June 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250609:nNDL1bGJtH:1","article_id":"2542386283","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2542386283","pubTimestamp":1749466819,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Metsera Inc. Announces Positive Phase 1 Trial Results for Once-Monthly Amylin Candidate MET-233i, Showing Promising Weight Loss and No Safety Concerns. Metsera Inc.  has announced positive topline results from its Phase 1 clinical trial of MET-233i, a once-monthly amylin analog. The trial demonstrated up to 8.4% mean placebo-subtracted weight loss at Day 36 and a 19-day half-life supporting monthly dosing. The results indicated that MET-233i was well-tolerated with no safety signals. The company plans to continue evaluating MET-233i both as a monotherapy and in combination with MET-097i. Topline data from the ongoing trials are anticipated by late 2025 or early 2026. Metsera will host a conference call and webcast on June 9, 2025, at 8:00 A.M. Eastern Time to discuss these findings.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for infor","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4588":"碎股","BK4112":"金融交易所和数据","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4139":"生物科技","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","MTSR":"Metsera Inc.","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","NDAQ":"纳斯达克OMX交易所"},"translate_title":"Metsera Inc.宣布每月一次的胰淀素候选药物MET-233i的积极1期试验结果，显示出有希望的减肥效果，并且没有安全问题","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MTSR":0.9,"NDAQ":0.9},"content_text":"Metsera Inc. Announces Positive Phase 1 Trial Results for Once-Monthly Amylin Candidate MET-233i, Showing Promising Weight Loss and No Safety Concerns\n    \n\n        Metsera Inc. (Nasdaq: MTSR) has announced positive topline results from its Phase 1 clinical trial of MET-233i, a once-monthly amylin analog. The trial demonstrated up to 8.4% mean placebo-subtracted weight loss at Day 36 and a 19-day half-life supporting monthly dosing. The results indicated that MET-233i was well-tolerated with no safety signals. The company plans to continue evaluating MET-233i both as a monotherapy and in combination with MET-097i. Topline data from the ongoing trials are anticipated by late 2025 or early 2026. Metsera will host a conference call and webcast on June 9, 2025, at 8:00 A.M. Eastern Time to discuss these findings.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metsera Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9465181-en) on June 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}